<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prevalence of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> is rapidly increasing, with severe socioeconomic impacts </plain></SENT>
<SENT sid="1" pm="."><plain>Excess <z:mpath ids='MPATH_42'>lipid deposition</z:mpath> in peripheral tissues impairs insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, and has been proposed to contribute to the pathology of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>However, few treatment options exist that directly target ectopic <z:chebi fb="23" ids="18059">lipid</z:chebi> accumulation </plain></SENT>
<SENT sid="3" pm="."><plain>Recently it was found that vascular endothelial growth factor B (VEGF-B) controls endothelial uptake and transport of fatty acids in heart and skeletal muscle </plain></SENT>
<SENT sid="4" pm="."><plain>Here we show that decreased VEGF-B signalling in <z:e sem="disease" ids="C1519106" disease_type="Experimental Model of Disease" abbrv="">rodent models</z:e> of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> restores insulin sensitivity and improves <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance </plain></SENT>
<SENT sid="5" pm="."><plain>Genetic deletion of Vegfb in diabetic db/db mice prevented ectopic <z:mpath ids='MPATH_42'>lipid deposition</z:mpath>, increased muscle <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake and maintained normoglycaemia </plain></SENT>
<SENT sid="6" pm="."><plain>Pharmacological inhibition of VEGF-B signalling by antibody administration to db/db mice enhanced <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance, preserved pancreatic islet architecture, improved Î²-cell function and ameliorated <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, key elements of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> and the <z:e sem="disease" ids="C0948265" disease_type="Disease or Syndrome" abbrv="">metabolic syndrome</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>The potential use of VEGF-B neutralization in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> was further elucidated in rats fed a high-fat diet, in which it normalized insulin sensitivity and increased <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake in skeletal muscle and heart </plain></SENT>
<SENT sid="8" pm="."><plain>Our results demonstrate that the vascular endothelium can function as an efficient barrier to excess muscle <z:chebi fb="23" ids="18059">lipid</z:chebi> uptake even under conditions of severe <z:hpo ids='HP_0001513'>obesity</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, and that this barrier can be maintained by inhibition of VEGF-B signalling </plain></SENT>
<SENT sid="9" pm="."><plain>We propose VEGF-B antagonism as a novel pharmacological approach for type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, targeting the <z:chebi fb="23" ids="18059">lipid</z:chebi>-transport properties of the endothelium to improve muscle insulin sensitivity and <z:chebi fb="105" ids="17234">glucose</z:chebi> disposal </plain></SENT>
</text></document>